Korean J Lab Med.  2006 Dec;26(6):436-441. 10.3343/kjlm.2006.26.6.436.

Evaluation of HBs Ag, HCV and HIV Ag-Ab Assays using Bio-Rad Elite Microplate Analyzer

• Hwang SH
• Oh HB
• Kim HS
• Lee EY

• KMID: 1889823
• DOI: http://doi.org/10.3343/kjlm.2006.26.6.436

Abstract

BACKGROUND: In this study, we evaluated the performance of Elite microplate analyzer (Bio-Rad Laboratories, France) and the related assays (ULTRA line) for the detection of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
METHODS
Seroconversion panels, HBsAg positive/HBsAg negative (n=99/n=1,422), anti-HCV positive/negative (n=97/n=1,670), and anti-HIV positive/negative (n=112/n=1,704) samples were used to evaluate the performance of Monolisa HBsAg ULTRA, Monolisa HCV Ag-Ab ULTRA, and Genscreen ULTRA HIV Ag-Ab, respectively. The agreement of Elite microplate analyzer with CODA analyzer (Bio-Rad Laboratories, CA, USA) was also evaluated.
RESULTS
The detection limit of Monolisa HBsAg ULTRA was 0.034 IU/mL. For Monolisa HBsAg ULTRA, Monolisa HCV Ag-Ab ULTRA, and Genscreen ULTRA HIV Ag-Ab, diagnostic sensitivities were all 100%, diagnostic specificities were 100%, 99.8% and 99.9%, and total CVs (coefficients of variation) were 13.8-17.5%, 3.4-5.2%, and 7.5-9.5%, respectively. The agreement of Elite microplate analyzer with CODA analyzer was 99.5%.
CONCLUSIONS
The performance of Elite microplate analyzer and the related assays on analytical sensitivity, precision, early detection, diagnostic sensitivity and specificity was all adequate for a mass screening. However, further large multi-center studies should be performed to validate our results.

Keyword

Hepatitis B virus; Hepatitis C virus; Human immunodeficiency virus; Evaluation; Sensitivity; Specificity; Elite Microplate Analyzer

MeSH Terms

Hepacivirus
Hepatitis B Surface Antigens
Hepatitis B virus
HIV*
Limit of Detection
Mass Screening
Sensitivity and Specificity
Hepatitis B Surface Antigens

Reference

References

1. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; Approved guideline. Document EP5-A.Vilanova, Pa: National Committee for Clinical Laboratory Standards;1999.

2. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159–74.

3. Hoofnagle JH. Posttransfusion hepatitis B. Transfusion. 1990; 30:384–6.

4. Weber B, Muhlbacher A, Melchior W. Detection of an acute asymptomatic HBsAg negative hepatitis B virus infection in a blood donor by HBV DNA testing. J Clin Virol. 2005; 32:67–70.

5. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001; 41:878–84.

6. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996; 334:1685–90.

7. Seo DH. Transfusion-transmitted diseases: current state and recent countermeasures. J Korean Med Assoc. 2006; 49:410–5.

8. Carman WF, Van Deursen FJ, Mimms LT, Hardie D, Coppola R, Decker R, et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology. 1997; 26:1658–66.

9. Howard CR. The structure of hepatitis B envelope and molecular variants of hepatitis B virus. J Viral Hepat. 1995; 2:165–70.

10. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBs-Ag. J Clin Microbiol. 2003; 41:135–43.

11. Weber B, Van der Taelem-Brule N, Berger A, Simon F, Geudin M, Ritter J. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. J Virol Methods. 2006; 135:109–17.

12. Weber B, Bayer A, Kirch P, Schluter V, Schlieper D, Melchior W. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol. 1999; 37:2639–47.

13. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004; 115:217–22.

14. Howard CR, Allison LM. Hepatitis B surface antigen variation and protective immunity. Intervirology. 1995; 38:35–40.

15. Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol. 1999; 59:19–24.

16. Louisirirotchanakul S, Kanoksinsombat C, Theamboonlert A, Puthavatana P, Wasi C, Poovorawan Y. Mutation of the “a” determinant of HBsAg with discordant HBsAg diagnostic kits. Viral Immunol. 2004; 17:440–4.

17. Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion. 1998; 38:56–9.

18. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005; 32:102–12.

19. Weber B. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol. 2006; 78(S1):):S59–65.

20. Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Ferey MP, Ebel A, et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol. 2006; 44:2321–6.

21. van Helden J, Denoyel GA. Experience with the IVDD performance evaluations of the ADVIA Centaur infectious disease assays. J Clin Virol. 2004; 30:S16–8.

22. Hennig H, Schlenke P, Kirchner H, Bauer I, Schulte-Kellinghaus B, Bludau H. Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods. 2000; 84:181–90.

23. Schappert J, Wians FH Jr, Schiff E, Smalley D, Gambardella R, Lee WM, et al. Multicenter evaluation of the Bayer ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay. Clin Chim Acta. 2006; 372:158–66.

24. Sickinger E, Stieler M, Kaufman B, Kapprell HP, West D, Sandridge A, et al. Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol. 2004; 42:21–9.

25. Kang HJ, Yoo KH, Kim HS, Cho HC. Evaluation of Abbott fourth generation HIV antigen and antibody assays. Korean J Lab Med. 2006; 26:39–44.

26. Laperche S, Bouchardeau F, Maniez M, Beolet M, Elghouzzi MH, Lefrere JJ. Nucleic acid testing in blood donations reactive to hepatitis C virus antibody, but with an extremely low viral load. Vox Sang. 2004; 86:198.

27. Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP. Performance characteristics of the ARCHITECT anti-HCV assay. J Clin Virol. 2005; 34:97–103.

28. Kwon JA, Yoon SY, Lee CK, Lim CS, Lee KN, Sung HJ, et al. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods. 2006; 133:20–6.

29. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005; 85:257–68.